Takeda Pharmaceuticals North America, Inc.'s Uloric (Febuxostat) Demonstrated Efficacy For Management Of Hyperuricemia In Patients With Gout, University of Chicago Study

EurekAlert! -- Philadelphia, October 17, 2009 – Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment.

Back to news